<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01120834</url>
  </required_header>
  <id_info>
    <org_study_id>0912010795</org_study_id>
    <nct_id>NCT01120834</nct_id>
  </id_info>
  <brief_title>Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)</brief_title>
  <official_title>Phase I/II Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory DLBCL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a phase I/II study of 5-azacitidine in combination with vorinostat in patients&#xD;
      with relapsed or refractory DLBCL. Combination therapy with methyltransferase inhibitors and&#xD;
      histone deacetylase inhibitors is highly synergistic in DLBCL cells, and both classes of&#xD;
      drugs can also synergize powerfully with standard anti-lymphoma chemotheraputics such as&#xD;
      doxorubicin in pre-clinical studies. We hypothesize that azacytidine + vorinostat combination&#xD;
      therapy will be safe and effective in selected patients with relapsed or refractory DLBCL. We&#xD;
      also hypothesize that patients demonstrating objective responses to this combination therapy&#xD;
      display specific epigenetic signatures, and that a biomarker or gene classifier can be&#xD;
      generated which will identify those patients likely to respond.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects will have biopsy proven relapsed or refractory DLBCL, have preserved&#xD;
      hematologic and other organ function, and have either progressed following or be&#xD;
      inappropriate candidates for autologous stem cell transplantation.&#xD;
&#xD;
      Patients will be treated with 5-azacitidine via subcutaneous administration and vorinostat&#xD;
      orally at four different dose levels as described below:&#xD;
&#xD;
        -  Dose level 1: azacitidine 55 mg/m2 on days 1-5 and oral vorinostat at 300 mg BID on Days&#xD;
           1-7.&#xD;
&#xD;
        -  Dose level 2: azacitidine 75 mg/m2 on days 1-5 and oral vorinostat at 200 mg BID on Days&#xD;
           1-7.&#xD;
&#xD;
        -  Dose level 3: azacitidine 55 mg/m2 on days 1-5 and oral vorinostat at 300 mg BID on Days&#xD;
           1-14.&#xD;
&#xD;
        -  Dose level 4: azacitidine 75 mg/m2 on days 1-5 and oral vorinostat at 200 mg BID on Days&#xD;
           1-14.&#xD;
&#xD;
      Each cycle will be of 28 days and patients will be treated for up to 6 cycles.&#xD;
&#xD;
      Up to 8 patients will be enrolled at each dose level. If at any time 2 patients in a given&#xD;
      cohort experience DLT, enrollment to that level will be discontinued.&#xD;
&#xD;
      Efficacy will be assessed by standard radiographic and other criteria at baseline and at the&#xD;
      end of treatment to determine ORR. Patients will be followed for 2 years or until disease&#xD;
      progression.&#xD;
&#xD;
      Tumor samples will be obtained for correlative studies at baseline through core needle or&#xD;
      surgical biopsy, with an additional biopsy performed on day 15 of cycle 1 as a&#xD;
      pharmacodynamic endpoint.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2010</start_date>
  <completion_date type="Actual">October 20, 2016</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>2 cycles</time_frame>
    <description>Overall Response Rate (ORR)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>all subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacytidine</intervention_name>
    <description>Dose level 1: azacitidine 55 mg/m2 on days 1-5&#xD;
Dose level 2: azacitidine 75 mg/m2 on days 1-5&#xD;
Dose level 3: azacitidine 55 mg/m2 on days 1-5&#xD;
Dose level 4: azacitidine 75 mg/m2 on days 1-5&#xD;
Each cycle = 28 days. Subjects may receive up to 6 cycles.</description>
    <arm_group_label>all subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>Dose level 1: oral vorinostat at 300 mg BID on Days 1-7.&#xD;
Dose level 2: oral vorinostat at 200 mg BID on Days 1-7.&#xD;
Dose level 3: oral vorinostat at 300 mg BID on Days 1-14.&#xD;
Dose level 4: oral vorinostat at 200 mg BID on Days 1-14.&#xD;
Each cycle = 28 days. Subjects receive up to 6 cycles.</description>
    <arm_group_label>all subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically confirmed diffuse large B cell lymphoma, relapsed&#xD;
             after or resistant to prior systemic therapy.&#xD;
&#xD;
          -  Subjects must have measurable disease on cross sectional imaging that is at least 1.5&#xD;
             cm in diameter.&#xD;
&#xD;
          -  Patients should have relapsed following or be deemed ineligible for autologous stem&#xD;
             cell transplantation. There is no limit to number of prior therapies.&#xD;
&#xD;
          -  Age &gt; = 18 years.&#xD;
&#xD;
          -  ECOG performance status &lt; = 2.&#xD;
&#xD;
          -  Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  ANC &gt; = 1,000/uL&#xD;
&#xD;
               -  platelets &gt; = 75,000//uL&#xD;
&#xD;
               -  total bilirubin &lt; = 2 X upper limit of normal&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) &lt; = 2.5 X upper limit of normal&#xD;
&#xD;
               -  Serum creatinine &lt; = 1.5 X upper limit of normal (ULN)&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test prior to&#xD;
             treatment&#xD;
&#xD;
          -  The effects of these investigational agents on the developing human fetus at the&#xD;
             recommended therapeutic doses are unknown. For this reason, women of child-bearing&#xD;
             potential and men must agree to use adequate contraception (hormonal or barrier method&#xD;
             of birth control; abstinence) prior to study entry and for the duration of study&#xD;
             participation. Should a woman become pregnant or suspect she is pregnant while&#xD;
             participating in this study, she should inform her treating physician immediately. A&#xD;
             woman who becomes pregnant while participating in the study must withdraw from the&#xD;
             study immediately.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior allogeneic transplant&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents.&#xD;
&#xD;
          -  Patients may not have previously received anti-lymphoma therapy with an HDAC inhibitor&#xD;
             (.e.g. Depsipeptide, MS-275, LAQ-824, PXD-101, and valproic acid). Patients who have&#xD;
             received an HDAC inhibitor for another indication such as epilepsy may enroll after a&#xD;
             30-day washout period&#xD;
&#xD;
          -  Patients with known active CNS lymphoma. Subjects with previous CNS lymphoma that have&#xD;
             been treated with chemotherapy, radiotherapy or surgery who have remained asymptomatic&#xD;
             for 90 days (3 months) and demonstrate, no CNS lymphoma, as shown by lumbar puncture,&#xD;
             CT scan or MRI, are eligible..&#xD;
&#xD;
          -  Patients with known hypersensitivity to azacytidine, vorinostat or mannitol.&#xD;
&#xD;
          -  Patients with a currently active second malignancy.&#xD;
&#xD;
          -  Uncontrolled illness including, but not limited to, ongoing or active infection,&#xD;
             symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or&#xD;
             psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements.&#xD;
&#xD;
          -  QTc interval &gt; 0.470. Consider discontinuation of medications that prolong QTc&#xD;
             interval to eliminate this exclusion if medically appropriate.&#xD;
&#xD;
          -  Pregnant and lactating women are excluded from the study because the risks to an&#xD;
             unborn fetus or potential risks in nursing infants are unknown.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>April 19, 2010</study_first_submitted>
  <study_first_submitted_qc>May 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2010</study_first_posted>
  <results_first_submitted>February 23, 2017</results_first_submitted>
  <results_first_submitted_qc>February 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2017</results_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diffuse large b cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
          <description>azacytidine: • Dose level 1: azacitidine 55 mg/m2 on days 1-5&#xD;
Dose level 2: azacitidine 75 mg/m2 on days 1-5&#xD;
Dose level 3: azacitidine 55 mg/m2 on days 1-5&#xD;
Dose level 4: azacitidine 75 mg/m2 on days 1-5&#xD;
Each cycle = 28 days. Subjects may receive up to 6 cycles.&#xD;
vorinostat: • Dose level 1: oral vorinostat at 300 mg BID on Days 1-7.&#xD;
Dose level 2: oral vorinostat at 200 mg BID on Days 1-7.&#xD;
Dose level 3: oral vorinostat at 300 mg BID on Days 1-14.&#xD;
Dose level 4: oral vorinostat at 200 mg BID on Days 1-14.&#xD;
Each cycle = 28 days. Subjects receive up to 6 cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>azacytidine: • Dose level 1: azacitidine 55 mg/m2 on days 1-5&#xD;
Dose level 2: azacitidine 75 mg/m2 on days 1-5&#xD;
Dose level 3: azacitidine 55 mg/m2 on days 1-5&#xD;
Dose level 4: azacitidine 75 mg/m2 on days 1-5&#xD;
Each cycle = 28 days. Subjects may receive up to 6 cycles.&#xD;
vorinostat: • Dose level 1: oral vorinostat at 300 mg BID on Days 1-7.&#xD;
Dose level 2: oral vorinostat at 200 mg BID on Days 1-7.&#xD;
Dose level 3: oral vorinostat at 300 mg BID on Days 1-14.&#xD;
Dose level 4: oral vorinostat at 200 mg BID on Days 1-14.&#xD;
Each cycle = 28 days. Subjects receive up to 6 cycles.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.5" lower_limit="27" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>Overall Response Rate (ORR)</description>
        <time_frame>2 cycles</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>Overall Response Rate (ORR)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
          <description>all subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>leucopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>raised ALP</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Martin, MD</name_or_title>
      <organization>Weill Cornell Medicine</organization>
      <phone>646.962.2064</phone>
      <email>amr2017@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

